Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT
PRODUCTS OF BIOSINO (SUZHOU) MEDICAL TECHNOLOGY CO., LTD. OBTAINING MEDICAL DEVICE REGISTRATION CERTIFICATE IN MALAYSIA

This announcement is made voluntarily by Biosino Bio-technology and Science Incorporation (the "**Company**", together with its subsidiaries, the "**Group**") to provide the shareholders and potential investors of the Company with the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the BioCyte series flow cytometers independently developed by Biosino (Suzhou) Medical Technology Co., Ltd. (中生(蘇州)醫療科技有限公司) ("**Biosino Medical**"), a subsidiary of the Company, have recently passed the review of the Medical Device Authority in Malaysia and officially obtained a Medical Device Registration Certificate in Malaysia, with registration number IVDA9463526–225393. The obtaining of the registration certificate signifies that the relevant products are qualified for lawful marketing, sale and use in Malaysia, and marks a solid step forward for the Company in expanding into the Southeast Asian market and serving global clinical and research users.

1. Basic Information of the Products

Product name	:	BioCyte series flow cytometers
Models	:	Including BioCyte-B5R3V7, BioCyte-B5R3V6 and a total of 10 models
Registration number	:	IVDA9463526–225393
Validity period of registration	:	From 10 February 2026 to 9 February 2031
Issuing authority	:	Medical Device Authority of Malaysia

2. Other Relevant Information of the Products

Flow cytometry technology is widely applied in clinical diagnostics and scientific research, providing technical support for disease diagnosis, immunological research and drug development. The BioCyte series flow cytometers, with stable performance and accurate testing results, have been applied in the domestic market.

Malaysia has stringent regulatory standards for medical device registration. Biosino Medical completed product testing, technical documentation submission and review procedures in accordance with relevant local regulatory requirements, and ultimately obtained approval from the Medical Device Authority in Malaysia. The products will be marketed in Malaysia through the local authorised representative, TRUST DIAGNOSTICS SDN BHD.

3. Impact on the Company and Risk Warning

The obtaining of the Medical Device Registration Certificate in Malaysia will facilitate the Group's expansion into the Southeast Asian market, enhance the Group's brand influence and market coverage in international markets, and is in line with the Group's international development strategy.

The obtaining of the above registration certificate is not expected to have a material impact on the financial position and operating results of the Group for the current year. The actual sales performance of the products in the local market may be subject to uncertainties arising from market conditions, regulatory policies, exchange rate fluctuations and market competition.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, China, 13 February 2026

As at the date of this announcement, the members of the Board comprise:

Chairman, President and Executive Director
Mr. Chen Peng

Vice Chairman and Executive Director
Mr. Li Zhonghua

Executive Director
Mr. Chen Zhengyong

Non-executive Director
Ms. Kang Rui

Independent non-executive Directors
Prof. Shen Jiangang, Mr. Fan Xiaoliang and Prof. Jin Tengchuan

This announcement is made in compliance with the requirements of the GEM Listing Rules to disclose information concerning the Company. The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the "Latest Listed Company Announcements" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company's website at www.zhongsheng.com.cn.